

sanofi-synthelabo

[View the current sanofi-synthelabo Page on BioPortfolio.com](http://www.bioportfolio.com/biorporate/9150-sanofi-synthelabo.html)

(<http://www.bioportfolio.com/biorporate/9150-sanofi-synthelabo.html>)

Contact Details:

leeg. 3-3

Vienna

Vienna

A-1140

Austria

Tel: ^8941286

Fax:

Email:

Recent Publications by sanofi-synthelabo:



- [Cannabis and the Course of Schizophrenia.](#)
*The discovery of two distinct cannabinoid receptors (CB1 and CB2) in the...*3rd October, 2008
Dr. Zullino receives or has received research support from the Swiss- Am J Psychiatry. 2008
Oct;165(10):1357-1358. ([DOI Direct Link](#))
- [Direct evidence for a furtive state in the degradation of carbasalatum calcicum.](#)
*The discovery of two distinct cannabinoid receptors (CB1 and CB2) in the...*30th August, 2008
Sanofi-SyntheLabo 371, Montpellier, France.- Angew Chem Int Ed Engl. 2004 May 10;43(20):2694-7.
- [Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.](#)
*Oxaliplatin (Eloxatin) is a third-generation platinum derivative with an...*9th December, 2006
Oncology Department, Sanofi-Synthelabo Recherche, F-34184 Montpellier- Mol Cancer Ther. 2006
Sep;5(9):2149-57. ([DOI Direct Link](#))
- [Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance.](#)
*The aim of this study was to compare the relative bioavailability and the...*9th December, 2006
Sanofi-Synthelabo Research (Sanofi-Aventis group), Chilly-Mazarin, France.- Fundam Clin Pharmacol.
2006 Aug;20(4):397-403. ([DOI Direct Link](#))
- [Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.](#)
*Neuropilin 2 (NRP2) is a receptor for the vascular endothelial growth...*13th September, 2006
Angiogenesis and Thrombosis Department, Sanofi-Synthelabo Research, 31036- Blood. 2006 Aug
15;108(4):1243-50. Epub 2006 Apr 18. ([DOI Direct Link](#))

- [\[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice\]](#)
*Patients with high blood pressure are often overweight or even obese....*5th August, 2006
Institut für Klinische Pharmakologie, Medizinische Fakultät, TU Dresden,- MMW Fortschr Med. 2004 Aug 5;146 Suppl 2:45-50.
- [Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.](#)
*Despite the well-documented effect of irbesartan, an angiotensin AT1...*8th June, 2006
Cardiovascular Research Department, Sanofi-Synthelabo Research, 1 Avenue- Eur J Pharmacol. 2006 Mar 18;534(1-3):271-9. Epub 2006 Mar 6. ([DOI Direct Link](#))
- [SSR181507, a dopamine D\(2\) receptor antagonist and 5-HT\(1A\) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.](#)
*RATIONALE: Selective attention deficit, characterised by the inability to...*11th April, 2006
Sanofi-Synthelabo Recherche, CNS Research, 371 Rue du Pr Blayac, 34184- Psychopharmacology (Berl). 2005 Aug;181(1):134-44. Epub 2005 Apr 14. ([DOI Direct Link](#))
- [Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice.](#)
*In diabetic patients, impairment of wound healing is a serious problem...*10th March, 2006
Cardiovascular Thrombosis Department, Sanofi-Synthelabo Recherche, 195- Eur J Pharmacol. 2006 Jan 4;529(1-3):172-8. Epub 2005 Dec 1. ([DOI Direct Link](#))
- [The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.](#)
*We investigated the molecular events involved in the long-lasting...*7th March, 2006
Oncology Research Department, Sanofi-Synthelabo Recherche, Montpellier,- FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11. ([DOI Direct Link](#))
- [rdIA, a new gene encoding a rhodanese-like protein in Halanaerobium congolense and other thiosulfate-reducing anaerobes.](#)
*The recently described anaerobic moderately halophilic bacterium...*4th February, 2006
Sanofi-Synthelabo Recherche, 31676 Labège Cedex, France.- Res Microbiol. 2005 Dec;156(10):1031-8. Epub 2005 Jul 13. ([DOI Direct Link](#))
- [Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.](#)
*Noncompetitive N-methyl-D-aspartate (NMDA) blockers induce...*25th January, 2006
CNS Department, Sanofi-Synthelabo Recherche, Bagneux, France.- Neuropsychopharmacology. 2005 Nov;30(11):1963-85. ([DOI Direct Link](#))
- [Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.](#)
*We investigated the effects of anandamide on peroxisome...*13th September, 2005
SANOFI-SYNTHELABO RECHERCHE, Oncology Department, 371 rue du Prof. Blayac,- Eur J Pharmacol. 2005 Jul 11;517(3):174-81. ([DOI Direct Link](#))
- [Two-sided tolerance intervals for balanced and unbalanced random effects models.](#)
*A procedure for constructing two-sided beta-content, gamma-confidence...*12th July, 2005
Preclinical and Research Statistics, Sanofi-Synthelabo Research Division,- J Biopharm Stat. 2005;15(2):283-93.
- [An overview of SSR149415, a selective nonpeptide vasopressin V\(1b\) receptor antagonist for the treatment of stress-related disorders.](#)
*Vasopressin (AVP) and corticotropin-releasing factor (CRF) are key...*14th June, 2005
Sanofi-Synthelabo Recherche, Exploratory Research Department, 195 route- CNS Drug Rev. 2005 Spring;11(1):53-68.

- [Evolution of Lipid Therapy: Combination Therapy and the Changing Landscape of CV Risk Reduction](#)
Medscape: Oct 3 2008 10:45PM Matching: sanofi synthelabo
- [Brain teasers](#)
Express Pharma: Sep 26 2008 6:32AM Matching: sanofi synthelabo
- [Sanofi-Aventis Acquires Zentiva For \\$2.6B](#)
Pharmaceutical Online: Sep 24 2008 11:51AM Matching: sanofi synthelabo
- [Managing Developmental Transitions in ADHD: Interdisciplinary Collaboration to Improve Care](#)
Abstracts in Hematology and Oncology: Sep 11 2008 7:12PM Matching: sanofi synthelabo
- [Unique Partnership to Offer Pharma Companies Comprehensive Suite of Medical Affairs Services](#)
Pharma Live: Jul 25 2008 7:16PM Matching: sanofi synthelabo

sanofi-synthelabo Patents:



- 6573386- [Process for the preparation of spiro\(4-cyclohexanone\)-\[3H\]indol\]-2-\[1'H\]-one derivatives](#)
- 6642258- [Use of central cannabinoid receptor antagonist for preparing medicines](#)
- 6649627- [Phenoxypropanolamines, method for the production thereof and pharmaceutical compositions containing the same](#)
- 6670338- [Pentasaccharides processes for their preparation and pharmaceutical compositions containing them](#)
- 6670486- [Process for racemization](#)
- 6673790- [Indolin-2-one derivatives, preparation and their use as oxytocin receptor ligands](#)
- 6680329- [N-\(heterocycl\)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants](#)
- 6686182- [Alkyl esters of 3-\(3,4-dihalophenyl\)-2,6-dioxopiperidine-3-propionic acid of use as intermediates](#)
- 6689797- [Tetrahydropyridines, preparation method and pharmaceutical compositions containing same](#)
- 6693118- [Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-.beta.1](#)
- 6710042- [Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them](#)
- 6642233- [1-Phenacyl-3-phenyl-3-\(piperidylethyl\)piperidine derivatives, process for the preparation thereof and pharmaceutical compositions containing them](#)
- 6639083- [Method for preparing a thiopene derivative](#)
- 6575939- [Device for automatic injection of a dose of medicinal product](#)
- 6585702- [Single-use device for injection](#)
- 6586456- [Aminothiazole derivatives and their use as CRF receptor ligands](#)
- 6596732- [1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same](#)
- 6600039- [PROCESS FOR THE PREPARATION OF](#)

[N-\(1,1-DIMETHYLETHYL\)-4-\[\[5'-ETHOXY-4-CIS\[2-\(4-MORPHOLINO\)ETHOXY\]-2'-OXOSP IRO\[CYCLOHEXAN-1,3'\[H\]INDOL\]1'\(2'-H\)-YL\]-SULFONYL\]-3-METHOXYBENZAMIDE AND ITS SALTS](#)

- 6610882- [N-\(arylsulphonyl\) amino acid derivatives](#)
- 6617336- [2-arylquinoline derivatives, preparation and therapeutic use thereof](#)
- 6624164- [1,3-dihydro-2H-indol-2-one derivatives, preparation method and pharmaceutical composition containing them](#)
- 6627649- [Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin V receptors, even of V1 a and V2 receptors](#)
- 6635645- [2,5,-diazabicyclo\[2.2.1\]heptane derivatives, their preparation and therapeutic uses](#)
- 6713053- [Use of IL-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular](#)
- 6730695- [1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for V1b and V1a arginine-vasopressin receptors](#)
- 6761879- [Titanium derived compounds, preparation and use thereof](#)
- 6861072- [Pharmaceutical composition with gastric residence and controlled release](#)
- 6864277- [1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them](#)
- 6867220- [Phenoxypropanolamines, method for producing them and pharmaceutical compositions containing them](#)
- 6894186- [Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates](#)
- 6908914- [Antipsychotic cyclic N-aralkylamines](#)
- 6908927- [Pyridopyranoazepine derivatives, their preparation and their therapeutic application](#)
- 6916929- [Method for preparing 4-methylamino-4-phenylpiperidine](#)
- 6918889- [Disposable injection device](#)
- 6949583- [Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same](#)
- 6979683- [Benzimidazole derivatives, preparation and therapeutic use thereof](#)
- 6858629- [Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same](#)
- 6852736- [Phenoxypropanolamines, preparation and therapeutic use thereof](#)
- 6767533- [Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress](#)
- 6794382- [Benzimidazole derivatives, preparation and therapeutic use thereof](#)
- 6800761- [Form of irbesartan, methods for obtaining said form and pharmaceutical compositions containing same](#)
- 6806282- [Branched substituted amino derivatives of 3-amino-1-phenyl-1h-\[1,2,4\]triazol, methods for producing them and pharmaceutical compositions containing them](#)
- 6828448- [Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate](#)
- 6835730- [4-heteroparyl-1,4-diazabicyclo\[3.2.2\]nonane, preparation and therapeutic use thereof](#)
- 6844329- [Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative](#)
- 6844335- [2-amino-3-\(alkyl\)-pyrimidone derivatives as GSK3..beta..inhibitors](#)
- 6844337- [1,4-diazabicyclo\[3.2.2\]nonane-phenylisoxazole derivatives, their preparation and their application in therapeutics](#)
- 6846936- [2-butyl-3-\(4-\[3\(dibutylamino\)propoxy\]benzoyl\)-5-nitro-benzofuran hydrochloride and preparation thereof](#)
- 7427615- [3-substituted-4-pyrimidone derivatives](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

